AXITINIB Targets Gatekeeper-Mutant BCR-ABL1(T315I)-Driven Leukemia in a Distinct And Selective Fashion

被引：0
|
作者：
Pemovska, T. [1 ]
Johnson, E. [2 ]
Kontro, M. [3 ,4 ]
Repasky, G. A. [1 ]
Chen, J. [2 ]
Wells, P. [2 ]
Cronin, C. [2 ]
McTigue, M. [2 ]
Kallioniemi, O. [1 ]
Porkka, K. [3 ,4 ]
Murray, B. W. [2 ]
Wennerberg, K. [1 ]
机构：
[1] Univ Helsinki, FIMM, Helsinki, Finland
[2] Pfizer Worldwide Res & Dev, Oncol Res Unit, San Diego, CA USA
[3] Univ Helsinki, Cent Hosp, Ctr Comprehens Canc, Helsinki, Finland
[4] Univ Helsinki, Helsinki, Finland
来源：
ANNALS OF HEMATOLOGY | 2015年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
51
引用
收藏
页码：S90 / S91
页数：2
相关论文
共 50 条
  • [41] Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia
    Gupta, Pranav
    Zhang, Guan-Nan
    Barbuti, Anna Maria
    Zhang, Xin
    Karadkhelkar, Nishant
    Zhou, Jingfeng
    Ding, Ke
    Pan, Jingxuan
    Yoganathan, Sabesan
    Yang, Dong-Hua
    Chen, Zhe-Sheng
    CANCER LETTERS, 2020, 472 : 132 - 141
  • [42] SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia
    Wang, Duowei
    Zheng, Yan
    Li, Jiaying
    Wu, Hongxi
    Li, Xianjing
    Tang, Ying
    Liu, Yang
    Li, Jiani
    Sun, Rui
    Zhou, Youli
    Sun, Jihong
    Yang, Yong
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2017, 811 : 117 - 124
  • [43] Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1
    Zhang, Hao
    Zhu, Mingsheng
    Li, Mingzi
    Ni, Duan
    Wang, Yuanhao
    Deng, Liping
    Du, Kui
    Lu, Shaoyong
    Shi, Hui
    Cai, Chen
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [44] Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34+ cells of patients with de novo chronic myeloid leukemia
    Jurcek, Tomas
    Razga, Filip
    Mazancova, Petra
    Musilova, Milena
    Dvorakova, Dana
    Borsky, Marek
    Zackova, Daniela
    Dobesova, Blanka
    Semerad, Lukas
    Mayer, Jiri
    Racil, Zdenek
    LEUKEMIA & LYMPHOMA, 2014, 55 (08) : 1915 - 1917
  • [45] Targeting the imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia through a novel BCR-ABL inhibitor
    Gupta, Pranav
    Kathawala, Rishil
    Wei, Liuya
    Wang, Fang
    Wang, XiaoKun
    Druker, Brian J.
    Fu, Li-Wu
    Chen, Zhe-Sheng
    CANCER RESEARCH, 2017, 77
  • [46] Quantitative monitoring of BCR-ABL mRNA harboring the T315I mutation in chronic myeloid leukemia (CML)
    Chomel, Jean-Claude
    Sorel, Nathalie
    Guilhot, Francois
    Turhan, Ali G.
    BLOOD, 2007, 110 (11) : 858A - 858A
  • [47] Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia
    Xu, L.
    Xu, Z.
    Zhang, X.
    Chen, H.
    Chen, Y.
    Huang, X.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S158 - S159
  • [48] Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia
    Xu, Lan-Ping
    Xu, Zheng-Li
    Zhang, Xiao-Hui
    Chen, Huan
    Chen, Yu-Hong
    Han, Wei
    Chen, Yao
    Wang, Feng-Rong
    Wang, Jing-Zhi
    Wang, Yu
    Yan, Chen-Hua
    Mo, Xiao-Dong
    Liu, Kai-Yan
    Huang, Xiao-Jun
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (06) : 1080 - 1086
  • [49] A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib
    Cea, Michele
    Cirmena, Gabriella
    Garuti, Anna
    Rocco, Ilaria
    Palermo, Claudia
    Cagnetta, Antonia
    Moran, Eva
    Colombo, Nicoletta
    Grasso, Raffaella
    Fugazza, Giuseppina
    Gobbi, Marco
    Nencioni, Alessio
    Ballestrero, Alberto
    Patrone, Franco
    LEUKEMIA RESEARCH, 2010, 34 (09) : E240 - E242
  • [50] THE PROSPECTIVE ANALYSIS OF LOW LEVEL BCR-ABL1 T315I MUTATION IN THE CD34+CELLS OF DE NOVO CML PATIENTS
    Jurcek, T.
    Razga, F.
    Mazancova, P.
    Dvorakova, D.
    Borsky, M.
    Zackova, D.
    Musilova, M.
    Semerad, L.
    Mayer, J.
    Racil, Z.
    HAEMATOLOGICA, 2013, 98 : 293 - 294
12345